Document:

Seperation Agreement

 Exhibit 10.29 

SEPARATION AGREEMENT 

THIS SEPARATION AGREEMENT (the “Agreement”) is made effective as of this
30th day of April, 2010, by and between John Thomas, a
natural person resident in Cobb County, Georgia and his heirs, assigns, executors, agents and representatives (the “Executive”), and SurgiVision, Inc., a Delaware corporation (“SurgiVision”). 

W I T N E S S E T H: 

WHEREAS, the Executive has been employed as the Chief Financial Officer of SurgiVision; 

WHEREAS, the Executive is irrevocably separating from employment with SurgiVision effective April 30, 2010 (the
“Employment Termination Date”); 
 WHEREAS, SurgiVision wishes to secure Executive’s cooperation to
assist in the transition of duties to SurgiVision’s new Chief Financial Officer for a period; 
 WHEREAS, it is the
desire of SurgiVision and the Executive to set forth herein their mutual agreement with respect to all matters relating to (i) the Executive’s separation from employment with SurgiVision; and (ii) the Executive’s release of
claims, all upon the terms set forth herein; 
 NOW, THEREFORE, for and in consideration of the mutual covenants and
promises contained herein, the parties hereby agree as follows: 
 1. Separation from Employment. Effective as of the
Employment Termination Date, the Executive irrevocably separates from all positions of employment with SurgiVision and its affiliates. This Agreement relates solely to Executive’s status as an employee and not as a director of SurgiVision
and/or any of its affiliates. The Executive’s employment with SurgiVision will continue until the close of business on the Employment Termination Date, at which time his employment with SurgiVision shall terminate. Following the Employment
Termination Date, the respective rights and obligations of the parties shall be governed by the terms of this Agreement. 
 2.
Cooperation. The Executive shall make himself available to consult and cooperate with SurgiVision representatives in connection with the orderly transition of his business responsibilities, and, in connection therewith, the Executive shall
exercise reasonable efforts to respond diligently to inquiries related to SurgiVision’s business. However, in no event will Executive’s consultation and cooperation services for SurgiVision after the Employment Termination Date exceed
twenty percent (20%) of Executive’s average level of services for SurgiVision for the thirty-six (36) month period prior to the Employment Termination Date. 

3. Payments and Benefits. 

(a) Provided that, prior to June 15, 2010, Executive has executed and delivered to SurgiVision, and has not revoked, the general
release referred to in Section 8 hereof (the “Release”) and the seven (7) day revocation period explained in Attachment A entitled 

 

 1 

 
“General Release” has expired, then SurgiVision will pay Executive the sum of Eighty Seven Thousand and 00/100 Dollars ($87,000.00), payable in twenty-four (24) semi-monthly
installments of Three Thousand Six Hundred Twenty Five and 00/100 Dollars ($3,625.00) each, subject to applicable withholdings and taxes, commencing June 15, 2010. Executive acknowledges that the payments referenced herein are consideration to
which he would not otherwise be entitled. 
 (b) The Executive acknowledges and agrees that the payments under this Agreement
are compensation and will be subject to the Executive’s usual withholding and included in the Executive’s W-2 earnings statement. 

4. Application of Code Section 409A. The provisions of this Agreement will be construed and applied in accordance with
Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”), and Treasury guidance issued thereunder to the extent applicable. SurgiVision shall report all payments and other benefits paid or provided pursuant to
Section 2 and Section 3 of this Agreement to the extent required by, and in accordance with, Section 409A of the Code (“Section 409A”). In the event that SurgiVision or the Executive reasonably and in
good faith determines that any payment to be made or benefit to be provided to the Executive hereunder would result in the application of Section 409A, SurgiVision shall, in consultation with the Executive, modify the Agreement to the extent
possible and in the least restrictive manner reasonably available in order to exclude such compensation from the definition of “deferred compensation” within the meaning of such Section 409A or in order to comply with the provisions
of Section 409A and/or any rules, regulations or other regulatory guidance issued under such statutory provision and without any diminution in the value of the payments to the Executive. Notwithstanding the foregoing, under no circumstance
shall SurgiVision be responsible for any taxes, penalties, interest or other losses or expenses incurred by the Executive due to any failure to comply with Section 409A, or for any interest on account of any delay in payment deemed necessary to
comply with Section 409A. 
 5. Acknowledgment. The Executive agrees that none of SurgiVision or any of its
predecessors, successors (by merger or otherwise), parents, subsidiaries, affiliated entities, divisions and assigns, together with each and every of their present, past and future officers, directors, stockholders, general partners, limited
partners, employees and agents and the heirs and executors of same (herein collectively referred to as the “Company Group”), has breached any oral or written contract that may have existed between the Executive and SurgiVision or
any member of the Company Group with respect to the Executive’s employment or termination of employment nor has SurgiVision or any member of the Company Group violated any law, statute, rule regulation or ordinance of any governmental authority
relating to the Executive’s employment. The Executive acknowledges that the payments and other consideration paid hereunder cannot and shall not be construed as any admission of liability or wrongdoing on the part of either SurgiVision or any
member of the Company Group. The Executive further acknowledges and agrees that the payments and other benefits being received by him pursuant to this Agreement satisfy any claim that he might have had under any SurgiVision policy or practice. The
Executive understands that the release provided for in Attachment A entitled “General Release” extends to all of the aforementioned claims and potential claims described therein which arose on or before the date of the execution of
this Agreement and that may arise on or before the Employment Termination Date, whether now known or unknown, suspected or 
  

 2 

 
unsuspected, and his participation as a member of any class asserting any such claims, and that this acknowledgement and release constitute essential terms of this Agreement. The Executive
understands and acknowledges the significance and consequence of this Agreement and of each specific release and waiver, and expressly consents that this Agreement shall be given full force and effect according to each and all of its express terms
and provisions, including those relating to unknown and unsuspected claims, demands, obligations, and causes of action, if any, as well as those relating to any other claims, demands, obligations or causes of action herein above-specified.

 6. Reinstatement. The Executive hereby waives any right or claim he may have to employment, re-instatement,
re-assignment or re-employment with SurgiVision or any member of the Company Group. The Executive’s acknowledgement and agreement as to these matters are material inducements for SurgiVision to make certain of its agreements, including, without
limitation, the agreement to make the payments in Section 3. 
 7. Non-Disclosure and Non-Competition
Agreement. The Executive acknowledges and agrees that the Non-Disclosure and Non-Competition Agreement made by the Executive dated September 1,2004 (the “NDA”) shall remain in full force and effect and that the terms of
such NDA are incorporated herein and made a part of this Agreement. The Executive agrees to comply with his continuing obligations under the NDA. 

8. Release. The Executive and SurgiVision shall execute and deliver a General Release in the form attached hereto as Attachment
A. 
 9. Successors. This Agreement shall inure to the benefit of and be enforceable by the Executive and by the
Executive’s personal or legal representatives, executors and administrators and by SurgiVision and its successors and assigns. 

10. No Admissions. Neither the execution of this Agreement by SurgiVision nor the terms hereof constitutes an admission by
SurgiVision, or by any agent or employee of SurgiVision or any member of the Company Group, of liability or unlawful conduct in any manner. 

11. Entire Agreement. Except with respect to the Executive’s continuing obligations pursuant to the NDA, this Agreement
contains the entire agreement of the parties with respect to the subject matter hereof, and shall be binding upon their respective heirs, executors, administrators, successors and assigns. 

12. Severability. If any term or provision of this Agreement shall be held to be invalid or unenforceable for any reason, then
such term or provision shall be ineffective to the extent of such invalidity or unenforceability without invalidating the remaining terms or provisions hereof, and such term or provision shall be deemed modified to the extent necessary to make it
enforceable. 
 13. Advice of Counsel. Executive represents and warrants that he has carefully read this Agreement, and
understands its contents, meaning and intent. SurgiVision hereby advises the Executive to consult with such advisors, including legal counsel, as seem appropriate to the Executive before signing this Agreement and Attachment A to this
Agreement entitled “General Release.” Understanding this document, the Executive has freely and voluntarily executed it, without compulsion, coercion or duress. 
  

 3 

 14. Amendments. Neither this Agreement nor any term hereof may be orally changed,
waived, discharged, or terminated, and may be amended only by a written agreement signed by both of the parties hereto. 
 15.
Governing Law. This Agreement shall be governed by the laws of the State of Tennessee without regard to the conflict of law principles of any jurisdiction. 

16. Legally Binding. The terms of this Agreement contained herein are contractual and not mere recitals. 

[The next page is the signature page] 
  

 4 

 IN WITNESS WHEREOF, the parties acknowledging that they are acting of their own free
will have voluntarily caused the execution of this Agreement as of this day and year written below. 
 EXECUTIVE ACKNOWLEDGES THAT HE HAS
READ THIS AGREEMENT, UNDERSTANDS IT, AND IS VOLUNTARILY ENTERING INTO IT. 
 PLEASE READ THIS AGREEMENT CAREFULLY. IT CONTAINS A RELEASE
OF ANY AND ALL KNOWN AND UNKNOWN CLAIMS. 
 SurgiVision, Inc. 

 

			
	By:	 	 /s/ Kimble Jenkins

	Name:	 	Kimble Jenkins
	Title:	 	President and Chief Executive Officer

  

	
	 /s/ John Thomas

	John Thomas

  

 5 

 ATTACHMENT A 

GENERAL RELEASE 

SurgiVision, Inc., a Delaware corporation (“SurgiVision”), and John Thomas (the “Executive”) enter into
this Release (this “Release”) on the      day of             , 2010. 

WITNESSETH 

WHEREAS, SurgiVision and the Executive are parties to a Separation Agreement made effective as of April 30, 2010 (the
“Separation Agreement”); 
 WHEREAS, as a condition to the receipt of certain benefits to be paid
following the date of this Release (the “Benefits”) under the Separation Agreement and in consideration for the execution and delivery of this Release by SurgiVision, the Executive has agreed to execute and deliver this Release; and

 WHEREAS, in consideration for the agreements and covenants of the Executive contained in the Separation Agreement and
the execution and delivery of this Release by the Executive, SurgiVision has agreed to execute and deliver this Release. 

NOW THEREFORE, in consideration of the covenants and mutual promises herein contained, it is agreed as follows: 

1. Release. The Executive, on behalf of himself and anyone claiming through the Executive, represents that he has not filed or
caused to be filed any lawsuit, complaint, or charge with respect to any claim this Release purports to waive. Executive hereby agrees not to sue SurgiVision or any of its divisions, subsidiaries, affiliates or other related entities of the above
specified entities (whether or not such entities are wholly owned) or any of the past, present or future directors, officers, administrators, trustees, fiduciaries, employees, agents or attorneys of SurgiVision or any of such other entities, or the
predecessors, successors or assigns of any of them (hereinafter referred to as the “Released Parties”), and hereby releases and discharges, fully, finally and forever, the Released Parties from any and all claims, causes of action,
lawsuits, liabilities, debts, accounts, covenants, contracts, controversies, agreements, promises, sums of money, damages, judgments and demands of any nature whatsoever, in law or in equity, both known and unknown, asserted or not asserted,
foreseen or unforeseen, which the Executive ever had or may presently have against any of the Released Parties arising from the beginning of time up to and including the date on which this Release is signed and delivered to SurgiVision, in any way
related to the Executive’s employment by SurgiVision, including, without limitation, any and all claims arising under: 

(a) Anti-discrimination statutes, such as the Age Discrimination in Employment Act (“ADEA”), and the Older
Workers Benefit Protection Act, which prohibit age discrimination in employment; Title VII of the Civil Rights Act of 1964, which prohibits discrimination or harassment based on race, color, national origin, religion, or sex; the Equal Pay Act
and/or the Lilly Ledbetter Fair Pay Act, which prohibit paying men and women unequal pay for equal work; the Americans With Disabilities Act and/or the Americans with Disabilities Act Amendments Act, which prohibit discrimination based on
disability; the Georgia Fair Employment Practices Act and any other federal, state or local law prohibiting employment discrimination, harassment, or retaliation of any kind. 

 

 Attachment A - 1 

 (b) Other laws, such as the Family and Medical Leave Act of 1993
(“FMLA”); any federal, state or local laws restricting an employer’s right to terminate an employee, or otherwise regulating employment; any federal, state or local laws enforcing express or implied employment contracts or
requiring an employer to deal with an employee fairly or in good faith; and any wage payment and collection law. 
 (c) Tort
and contract claims, such as claims for wrongful or constructive discharge, negligence, physical or personal injury, emotional distress, fraud, fraud in the inducement, negligent misrepresentation, defamation, invasion of privacy, interference
with contract or with prospective economic advantage, breach of oral, express or implied contract, breach of covenants of good faith and fair dealing, and similar or related claims. 

(d) Other released claims, including, without limitation, claims: (i) under the Employee Retirement Income Security Act
of 1974; (ii) for compensation, stock options, bonuses, or lost wages; (iii) in any way related to design or administration of any employee benefits program; (iv) for severance or similar benefits or for post-employment health or
group insurance benefits; or (v) for fees, costs or expenses of any attorneys who represent or have represented Executive. 

(e) Unknown claims: Executive understands that he is releasing the Released Parties from claims that he may not know about as
of the date hereof and that this is his knowing and voluntary intent even though someday he might learn that some or all of the facts he currently believes to be true are untrue and even though he might then regret having signed this Release.
Executive is expressly assuming that risk and agrees that this Release shall remain effective in all respects in any such case. Executive expressly waives all rights he might have under any law that is intended to protect him from waiving unknown
claims, and Executive understands the significance of doing so. 
 (f) Nothing contained in this Release shall apply to, or
release SurgiVision from any obligation (i) contained in the Separation Agreement or this Release, (ii) to indemnify Executive as required by §145 of the Delaware General Corporation Law and SurgiVision’s bylaws or
(iii) with respect to any vested benefit with respect to the Executive pursuant to any employee benefit or equity plan of SurgiVision other than any severance or retention program or practice. 

(g) The Executive acknowledges that the consideration offered in connection with the Separation Agreement was and is in part for this
Release and such portion of such consideration is accepted by the Executive as being in full accord, satisfaction, compromise and settlement of any and all claims or potential claims, and the Executive expressly agrees that the Executive is not
entitled to, and shall not receive, any further recovery of any kind from SurgiVision or any of the other Released Parties, and that in the event of any further proceedings whatsoever based upon any matter released herein, neither SurgiVision nor
any of the other Released Parties shall have any further monetary or other obligation of any kind to the Executive, including any obligation for any costs, expenses or attorneys’ fees incurred by or on behalf of the Executive, except as
provided in the Separation Agreement or in this Release. 
  

 Attachment A - 2 

 2. FMLA and FLSA Rights Honored. Executive acknowledges that he has
received all of the leave from work for family and/or personal medical reasons and/or other benefits to which he believes he is entitled under SurgiVision’s policy and FMLA. Executive has no pending request for FMLA leave. SurgiVision has not
mistreated Executive in any way because of any illness or injury to Executive or any member of his family. Executive has received all monetary compensation, including hourly wages, salary and/or overtime compensation, to which he believes he is
entitled under the Fair Labor Standards Act (“FLSA”). 
 3. ADEA Release Requirements
Satisfied. Executive understands that this Release has to meet certain requirements to validly release any ADEA claims Executive might have had, and Executive represents and warrants that all such requirements have been satisfied.
SurgiVision hereby advises Executive that before signing this Release, he may take twenty-one (21) days to consider this Release. Executive acknowledges that: (1) he took advantage of as much of this period to consider
this Release as he wished before signing; (2) he carefully read this Release; (3) he fully understands it; (4) he entered into this Release knowingly and voluntarily (free from fraud, duress, coercion, or mistake of fact);
(5) this Release is in writing and is understandable; (6) in this Release, he waives current ADEA claims; (7) he has not waived future ADEA claims; (8) he is receiving valuable consideration in exchange for execution of this
Release that he would not otherwise be entitled to receive; and (9) SurgiVision hereby advises Executive in writing to discuss this Release with his attorney (at his own expense) prior to execution, and he has done so to the extent he deemed
appropriate. 
 4. Review & Revocation. 

(a) Review: Before executing this Release, Executive may take twenty one (21) days to consider this
Release. Executive acknowledges and agrees that his waiver of rights under this Release is knowing and voluntary and complies in full with all criteria of the regulations promulgated under the Age Discrimination in Employment Act, the Older
Workers Benefit Protection Act, Title VII of the Civil Rights Act of 1964, and any and all federal, state and local laws, regulations and orders. SurgiVision hereby advises Executive in writing to consult with an attorney prior to
executing this Release. In the event that Executive executes this Release prior to the expiration of the twenty-one (21) day period, he acknowledges that his execution was knowing and voluntary and not induced in any way by SurgiVision
or any other person. 
 (b) Revocation: For a period of seven (7) days following his
execution of this Release, Executive may revoke this Release. If he wishes to revoke this Release, he must revoke in writing delivered by hand or confirmed facsimile prior to the end of the seventh
(7th) day of the revocation period to Oscar Thomas,
One Commerce Square, Suite 2550, Memphis, TN 38103, (901) 522-9400 (fax) or the revocation will not be effective. If Executive timely revokes this Release, all provisions hereof will be null and void, including any and all payments
referenced in the Separation Agreement to which this Release is attached. If Executive does not advise Oscar Thomas in writing that he revokes this Release within seven (7) days of his execution of it, this Release shall be forever
enforceable. The eighth (8th) day following
Executive’s execution of this Release shall be the Effective Date of this Release. This Release is not effective or enforceable until the revocation period has expired. 

 

 Attachment A - 3 

 5. No Assignment of Claims. The Executive expressly represents and warrants that he
is the sole owner of the actual and alleged claims, demands, rights, causes of action and other matters that are released herein, that the same have not been transferred or assigned or caused to be transferred or assigned to any other person, firm,
corporation or other legal entity, and that he has the full right and power to grant, execute and deliver the general release, undertakings and agreements contained herein. 

6. Release by SurgiVision. SurgiVision hereby releases the Executive from any and all claims, demands or causes of action of any
kind that it now has against the Executive arising out of or related to the Executive’s employment with SurgiVision, with the exception of claims, demands or causes of action arising out of or related to criminal acts, fraud or knowing wrongful
conduct, that arise out of or relate to any occurrences prior to the date of this Release; provided, however, that nothing contained in this Release shall apply to, or release the Executive from, any obligation contained in the Separation Agreement,
the NDA (as that term is defined in the Separation Agreement) or this Release. 
 7. Entire Agreement. The Separation
Agreement, the NDA and this Release constitute the entire agreement and understanding between the parties. The Executive has not relied on any oral statements that are not expressly stated in the Separation Agreement or this Release. 

8. Governing Law. This Release shall be governed by, and construed and enforced in accordance with, the internal laws of the State
of Tennessee without regard to the principle of conflicts of laws. 
 SurgiVision, Inc. 

 

			
	 By:
	 	  

	 Name:
	 	  

	 Title:
	 	  

 

	
	  

	John Thomas

  

 Attachment A - 4SurgiVision, Inc. Cardiac EP Business Participation Plan

 Exhibit 10.30 

SURGIVISION, INC. 

CARDIAC EP BUSINESS PARTICIPATION PLAN 

INTRODUCTION 
 The
SurgiVision, Inc. Cardiac EP Business Participation Plan (the “Plan”) provides a key product development advisor and consultant to the Company (as defined herein) with the opportunity to receive a payment (a “Liquidity Payout”)
upon consummation of a Liquidity Event (as defined herein) in accordance with the terms and conditions set forth herein. 
  

	1.	DEFINITIONS 

Whenever used herein, the following words and phrases shall have the meanings set forth below: 

“AAA” shall have the meaning as set forth in Section 6.5 herein. 

“Affiliate” of a Person shall mean any other Person that controls, is controlled by, or is under common control with, such
Person. 
 “Award Agreement” shall mean that certain letter agreement entered into between the Company and Participant
pursuant to the Plan, as described in Section 3.1 below, as the same may be amended or modified. 
 “Board” shall
mean the board of directors of the Company. 
 “Cardiac EP Business Unit” shall mean and include that segment of the
Company’s business operations relating to catheter-based MRI-guided cardiac EP to treat cardiac arrhythmias. For the avoidance of doubt, (a) the Cardiac EP Business Unit includes the Company’s operations relating to the ClearTrace
Cardiac Intervention System for MRI-guided cardiac EP to treat cardiac arrhythmias; and (b) the Cardiac EP Business Unit does not include the Company’s operations relating to the ClearPoint Neuro Intervention System, the SafeLead
Development Program or any other Company products or product candidates. 
 “Company” shall mean SurgiVision, Inc., a
Delaware corporation, including its successor in interest by merger, consolidation or otherwise. 
 “Competing
Activities” shall have the meaning as set forth in Section 4.2 herein. 
 “Contingent Payments” shall have
the meaning as set forth in Section 3.3 herein. 
 “Dilution Factor” shall have the meaning as set forth in
Section 3.4(c) herein. 
 “Dispute” shall have the meaning as set forth in Section 6.5 herein. 

 “Expiration Date” shall mean June 2, 2025. 

“Field” shall mean the field of MRI-guided, catheter-based cardiac EP to treat cardiac arrhythmias. For the avoidance of any
doubt, the field of MRI-guided, catheter-based EP to treat cardiac arrhythmias includes not only the actual MRI-guided cardiac intervention but also the pre-operative and post-operative planning and/or assessment directly associated with the
MRI-guided cardiac intervention; however, it does not include diagnostic, assessment, and triage activity not directly associated with the MRI-guided cardiac intervention (e.g., diagnostic devices and services to assist healthcare professionals and
patients evaluate treatment options). 
 “Good Standing” shall mean that Participant: (a) continues to comply in
all material respects with the policies of any hospital at which he is granted admitting and clinical privileges and any university at which he is member of the faculty; and (b) is not debarred, excluded, suspended or otherwise determined to be
ineligible to participate in any federal healthcare program as a result of Participant’s affirmative act of malfeasance (e.g., not because of Participant ceasing to work or losing his work status in the United States or any other reason
unrelated to malfeasance). 
 “Liquidity Event” shall mean (a) in the case of the Cardiac EP Business Unit, the
sale or other disposition of all or substantially all of (i) the Company’s interest in or (ii) the assets of the Company used in the operation of, the Cardiac EP Business Unit to another Person (other than a transfer to the
Company’s Affiliate); and (b) in the case of the Company as a whole, any of the following events: 
  

	 	(i)	the sale or other disposition of all or substantially all of the assets of the Company to any Person (other than a transfer to the Company’s Affiliate); or

  

	 	(ii)	a share exchange, merger, takeover (hostile or friendly) or other business combination transaction, wherein less than a majority of the combined voting power of the
then outstanding securities of the surviving entity immediately after such transaction are held in the aggregate by the holders of the Company’s securities entitled to vote generally in the election of directors of the Company immediately prior
to such transaction. 

 “Liquidity Payout” shall have the meaning as set forth in the Introduction
herein. 
 “Participant” shall mean Dr. Nassir F. Marrouche. 

“Participation Interest” shall mean the percentage set forth in Participant’s Award Agreement and used to determine the
amount of any Liquidity Payout, which percentage shall be subject to adjustment as provided in Section 3.4 herein. 

“Person” shall mean an individual, a partnership, a corporation, a limited liability company, an association, a joint stock
company, a trust, a joint venture, an unincorporated organization and a governmental entity or any department, agency or political subdivision thereof. 
  

 2 

 “Qualified Financing” shall have the meaning as set forth in Section 3.4(b)
herein. 
 “Rules” shall have the meaning as set forth in Section 6.5 herein. 

“Transaction Value” shall have the meaning set forth in Section 3.2(a) or 3.2(b) herein, as the case may be. 

 

	2.	ADMINISTRATION 

The Plan shall be administered by the Board. The Board shall have the authority, consistent with the terms of the Plan: (a) to
calculate and determine the amount of the Transaction Value; (b) to interpret the terms and provisions of the Plan and Participant’s Award Agreement; and (c) to supervise the administration of the Plan as described herein or
otherwise. Subject to the foregoing, all decisions made by the Board pursuant to the provisions of the Plan shall be made in the Board’s sole discretion and in good faith and shall be final and binding on all Persons. 

 

	3.	LIQUIDITY PAYOUT AMOUNTS 

3.1 Award Agreement. Participant’s award under the Plan, shall be evidenced by the Award Agreement entered into between the
Company and Participant. 
 3.2 Liquidity Payout Following Liquidity Event. Upon the occurrence of a Liquidity Event with
respect to the Cardiac EP Business Unit or the Company, the Participant’s right to a payment will vest and the Company or its successor in interest, as applicable, will pay to Participant a Liquidity Payout as follows: 

 

	 	(a)	If the Liquidity Event occurs solely with respect to the Cardiac EP Business Unit, a Liquidity Payout will be made to Participant based on the following calculation:
(i) the transaction value paid to the Company or its stockholders upon closing of the Liquidity Event (“Transaction Value”), multiplied by (ii) the Participant’s then current Participation Interest. 

 

	 	(b)	If the Liquidity Event occurs with respect to the Company, as a whole, the Board will determine, in consultation with the Company’s financial advisors and
Participant, a reasonable allocation of transaction value to the Cardiac EP Business Unit. Based on that allocation to the Cardiac EP Business Unit, a Liquidity Payout will be made to the Participant based on the following calculation:
(i) Transaction Value allocated to the Cardiac EP Business Unit, multiplied by (ii) the Participant’s then current Participation Interest. 

  

	 	(c)	If the Company and/or its stockholders receive non-cash consideration in connection with the Liquidity Event, then the Company or its successor in interest, as
applicable, may, without obligation, fund the Liquidity Payout with cash and/or such non-cash consideration in the same proportion that the Company and/or its stockholders receive such consideration in connection with the Liquidity Event. Non-cash
consideration shall be valued in good faith by the Board, in consultation with the Company’s financial advisors and Participant. 

  

 3 

 3.3 Payment. A Liquidity Payout resulting from the occurrence of a Liquidity Event
will be made within thirty (30) days following the Liquidity Event. In the event that the Company or its stockholders may receive any payments (“Contingent Payments”) after the closing of the Liquidity Event which payments are subject
to any substantial contingencies as of the closing which are not within the control of the Company, its stockholders or Participant, then for purposes of computing the Liquidity Payout due within thirty (30) days of the Liquidity Event, the
Transaction Value shall not include such Contingent Payments or any estimated value thereof, but the removal of the contingencies to the right of the Company or its stockholders to a Contingent Payment shall be considered a separate vesting event
for Participant and shall entitle Participant to a Liquidity Payout within sixty (60) days of such event based on the amount of the Contingent Payment then no longer subject to contingencies. 

3.4 Dilution of Participation Interest. 
  

	 	(a)	Participant’s Participation Interest will be equitably reduced to take into account and reflect any direct investment into, or any direct financing of, the Cardiac
EP Business Unit (i.e., not an investment in or financing of the Company as a whole). For the avoidance of any doubt, this would include a monetary investment in the Cardiac EP Business Unit by the Company in lieu of third-party financing.

  

	 	(b)	Participant’s Participation Interest will be subject to dilution in the event of a Qualified Financing of the Company. A “Qualified Financing” means a
financing transaction occurring after the effective date of the Plan in which the Company issues shares of its common stock, or securities convertible (directly or indirectly) into shares of its common stock, in exchange for cash proceeds. Solely as
an example and without limiting the generality of the foregoing definition, the initial public offering of shares of the Company’s common stock will constitute a Qualified Financing. 

 

	 	(c)	Following each Qualified Financing, Participant’s Participation Interest will be reduced by multiplying his Participation Interest in effect immediately prior to
the Qualified Financing by the Dilution Factor. Such “Dilution Factor” will be calculated in the following manner: 

Dilution Factor = 1 – ((Post Shares – Pre Shares) ÷ Post Shares), where: 

Pre Shares means the number of Issued and Outstanding Shares immediately prior to the Qualified Financing; 

Post Shares means the number of Issued and Outstanding Shares immediately following the Qualified Financing; and 

Issued and Outstanding Shares means, as of a given date/time, the total number of shares of the Company’s common stock
(a) issued and outstanding, and (b) issuable upon the conversion of any and all outstanding securities convertible into shares of the Company’s common stock, whether then convertible. 

 

 4 

	4.	ELIGIBILITY FOR LIQUIDITY PAYOUT 

4.1 Eligibility. Participant’s right to receive any Liquidity Payout will be subject to and conditioned on the following:

  

	 	(a)	Participant must disclose this Plan to, and seek the approval of, the University of Utah Conflicts of Interest Committee within ninety (90) days following the
effective date of this Plan; 

  

	 	(b)	The University of Utah Conflicts of Interest Committee must review and approve in writing Participant’s participation in this Plan; 

 

	 	(c)	Participant must not engage in any material Competing Activities during the term of the Plan; 

 

	 	(d)	To the extent Participant serves as a consultant to or employee of the Company, the Participant’s consultancy or employment must not be terminated by the Company
for cause during the term of the Plan; 

  

	 	(e)	Participant must remain in Good Standing during the term of the Plan; and 

  

	 	(f)	Participant must comply, in all material respects, with applicable disclosure and/or reporting obligations regarding Participant’s relationship with and interest
in the Company, during the term of the Plan. 

 4.2 Competing Activities. For purposes of the Plan,
Participant shall be deemed to have engaged in “Competing Activities” if Participant, directly or indirectly through one or more intermediaries, (a) owns (other than ownership of a publicly-held companies in an amount less than 0.1%
of the outstanding shares of such company), manages, operates, finances or controls, (b) is employed by or associated with, (c) consults for or otherwise render services to, or (iv) lends his name or credit to, any business whose
products, activities or services compete anywhere in the world with products, activities or services (or proposed products, activities or services) of the Cardiac EP Business Unit in the Field. For the avoidance of any doubt, the term
“Competing Activities” (i) in no way restricts or inhibits Participant’s ability to engage in the practice of medicine or Participant’s use of any product that is for patient care or treatment, it being understood that
Participant directs all medical decisions regarding the care and treatment of his patients and Participant assumes full responsibility for any clinical decisions made in connection with the care and treatment of his patients; and (ii) does not
include Participant’s involvement with eCardio Diagnostics, Marrek, the University of Utah or other universities or hospitals (foreign or domestic), so long as those entities’ products, activities or services do not compete in whole or in
material part anywhere in the world with products, activities or services (or proposed products, activities or services) of the Cardiac EP Business Unit in the Field. 

4.3 Death. In the event of Participant’s death within three (3) years prior to the occurrence of a Liquidity Event, the
Company will make any Liquidity Payout resulting from the Liquidity Event to Participant’s estate, assuming Participant otherwise satisfied all of the conditions set forth in Section 4.1 above through the date of his death). 

 

 5 

	5.	AMENDMENT 

At any time prior to the consummation of a Liquidity Event, the Board may amend or alter (a) this Plan and/or
(b) Participant’s Award Agreement issued under this Plan. Notwithstanding the foregoing, no amendment or alteration of this Plan or Participant’s Award Agreement shall impair Participant’s rights under this Plan, without
Participant’s prior consent. 
  

	6.	MISCELLANEOUS 

6.1 Taxes. Liquidity Payouts are subject to applicable federal, state, and local withholding taxes. The Company shall withhold from
Liquidity Payouts payable under the Plan all income, employment and payroll taxes which, by applicable federal, state or local law, the Company is required to withhold. 

6.2 Consultancy Status Not Conferred. The adoption of this Plan and the receipt of an award under this Plan shall not confer upon
Participant any right to continued consultancy with the Company or its subsidiaries, as the case may be, nor shall it interfere in any way with the right of the Company or its subsidiaries to terminate the Participant’s consultancy. 

6.3 Governing Law. The Plan and all awards made and actions taken thereunder shall be governed by and construed in accordance with
the laws of the State of Delaware. 
 6.4 Successors. In the event of any merger, consolidation or other similar event
involving the Company, the provisions of the Plan shall be binding upon the surviving or resulting entity of such transaction. 

6.5 Arbitration. Any controversy, claim or dispute arising out of, in connection with or relating to this Plan or any Incentive
Award Agreement (“Dispute”), which cannot otherwise be resolved through good faith negotiations between the parties, may be submitted by either the Company or Participant to binding arbitration in accordance with the then prevailing
Commercial Arbitration Rules of the American Arbitration Association (the “AAA”), except as such rules conflict with the provisions of this Section, in which case the provisions of this Section shall control. The Dispute shall be submitted
to binding arbitration before three (3) arbitrators in Memphis, Tennessee under the AAA’s Commercial Arbitration Rules (the “Rules”) as modified or supplemented hereby. Within ten (10) days after commencement of any
arbitration proceeding, as provided herein, the Company shall choose an arbitrator, and Particpant shall choose an arbitrator. Thereafter, a third neutral arbitrator shall be selected by the two (2) arbitrators chosen by the parties. If the
arbitrators chosen by the parties cannot agree upon the neutral arbitrator within ten (10) business days after their appointment, then, in any such event, the neutral arbitrator shall be selected, pursuant to the Rules. The costs of the
arbitration, including the fees and expenses of the arbitrators, shall be shared equally by the parties, but each party shall be responsible for its own costs, including attorneys and witness fees, incurred by that party in the arbitration
proceedings. In rendering an award, the parties agree that the arbitrators shall not have any power or authority to modify any provisions of the Plan or Participant’s Award Agreement, and in no event shall the arbitrator have the power or
authority to make awards that provide for damages expressly excluded or limited by the same. The arbitration award shall be in writing and shall specify the factual or legal basis for the award.

  

 6 

 
A judgment upon the award rendered by the arbitrators may be entered in any court having jurisdiction thereof. Nothing in this Section shall be construed to prevent any party from instituting
legal proceedings to seek a temporary restraining order or other temporary or preliminary injunctive relief to prevent immediate and irreparable harm to such party, and for which monetary damages would be inadequate, pending final resolution of a
Dispute pursuant to this Section. Except as necessary in court proceedings to enforce this arbitration provision or an award rendered hereunder or to obtain interim relief, and except as reasonably necessary to comply with any applicable law, rule,
regulation of any governmental authority or securities exchange, neither party may, nor may the arbitrator, disclose the existence, content or results of any arbitration hereunder without the prior written consent of both parties. The Federal
Arbitration Act, 9 U.S.C. Sections 1 through 14, except as modified hereby, shall govern the interpretation and enforcement of this Section. THE PARTIES ACKNOWLEDGE AND AGREE THAT IN AGREEING TO SUBMIT ALL DISPUTES TO BINDING ARBITRATION, THEY ARE
IRREVOCABLY WAIVING ANY AND ALL RIGHTS THEY MAY HAVE TO A TRIAL BY JURY IN ANY JUDICIAL PROCEEDING INVOLVING ANY CLAIM RELATING TO THIS AGREEMENT. 

6.6 No Trust. The amounts to be paid in respect of the Plan shall not constitute or be treated as a trust of any kind. The Company
shall not be required to fund or otherwise segregate assets to be used for the payment of a Liquidity Payout under the Plan. The Company shall make such payments only out of its general assets, and, therefore, the Company’s obligation to make
such payments shall be subject to any claims of its other creditors having priority as to its assets. Participant’s rights under the Plan are solely those of a general unsecured creditor of the Company and are subject to forfeiture under the
terms hereof and under Participant’s Award Agreement. If the Company designates any assets to pay its liabilities hereunder, such assets shall at all times remain the property of the Company, and Participant shall not have any property interest
in such assets. 
 6.7 Interpretation. The Board, acting in good faith, shall have discretion to interpret the Plan and
Participant’s Award Agreement. The Board’s interpretation and actions hereunder, if made in the exercise of good faith discretion and not in an arbitrary and capricious manner, shall be conclusive and binding upon all Persons for all
purposes. Neither the Company nor any of its directors, officers or employees (including members of the Board) shall be liable to Participant or any other Person for any action taken in connection with the interpretation of the Plan or
Participant’s Award Agreement. 
 6.8 No Right of Equity Ownership. Neither the Plan nor Participant’s Award
Agreement grants to Participant any right or privilege of equity ownership in the Company. 
 6.9 Assignment.
Participant’s rights under the Plan and his Award Agreement may not be transferred, conveyed, encumbered or assigned, whether voluntarily or involuntarily 

6.10 Section 409A Compliance. The foregoing provisions of this Plan are intended to cause the Plan to conform with the
requirements of a plan providing only for short-term deferrals as provided in Treasury Regulation §1.409A-1(b)(4), as amended from time to time or to any successor provision, and the provisions of this Plan shall be construed in accordance with
that intention. If any provision of this Plan shall be inconsistent or in conflict with any applicable 
  

 7 

 
requirements for a short-term deferral plan, then such requirement shall be deemed to override and supersede the inconsistent or conflicting provision, and any required provision of a short-term
deferral plan that is omitted from this Plan shall be incorporated herein by reference and shall apply retroactively, if necessary, and be deemed to be a part of this Plan to the same extent as though expressly set forth herein. To the extent
permissible under Treasury Regulation §1.409A-1(b)(4)(ii), the payments may be delayed within the discretion of the Board on the following grounds: (a) it is administratively impracticable to make the payment by the regular payment date
due to unforeseeable reasons; (b) the payment would jeopardize the Company’s ability to continue as a going concern; (c) the payment is reasonably anticipated not to be deductible under Section 162(m) of the Code due to
circumstances that a reasonable person would not have anticipated; or (d) such other grounds as may be from time to time be permissible under the foregoing regulation; provided, however, any delayed payment shall be made within the period
required under the foregoing regulation. 
  

	7.	EFFECTIVENESS OF PLAN, PLAN TERMINATION 

This Plan shall become effective on June 2, 2010, and shall expire and terminate, together with the Award Agreement, upon the earlier
to occur of (a) the Expiration Date, or (b) the consummation of a Liquidity Event of the Cardiac EP Business Unit or the Company; provided, however, that upon the occurrence of such Liquidity Event, the terms of the Plan (and the Award
Agreement) shall survive to the extent, but only to the extent, necessary for the Company to satisfy its obligations to Participant hereunder. 
  

 8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00174-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00174-of-00352.parquet"}]]